Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: A Canadian multicentre trial

Canadian Journal of Gastroenterology

Volumn 21, Issue 2, 2007, Pages 91-95

  Chatterjee, A ^a   Swain, M G ^b   Lee, S S ^b   Bain, V G ^c   Peltekian, K ^d   Croitoru, K ^e   Adams, P C ^f   Kaita, K ^g   Teitel, J ^a   Heathcote, E Jenny ^a,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Chronic hepatitis C; Hemophilia; Induction dosing; Interferon; Repairing

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BODY MASS; CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETHARGY; LEUKOCYTE COUNT; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYALGIA; NIGHTMARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SEX DIFFERENCE; SIDE EFFECT; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

EID: 33947265559     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/817198     Document Type: Article

References (21)

1. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-31.
2. Lichterfeld M, Schmeisser N, Qurishi N, et al. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005;50:221-8.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIRC, and DOSVIRC groups. Lancet 1997;349:825-32.
4. Dughera L, Battaglia E, Serra AM, et al. Human leukocyte interferon-alpha treatment for chronic HCV-related hepatitis in hemophilic patients previously intolerant to other interferon-alpha. Dig Dis Sci 2002;47:427-31.
5. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993;85:1138-48.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
8. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
9. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-31.
10. Brouwer JT, Nevens F, Kleter, B et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998;28:951-9.
11. Perez R, Jimenez M, Crespo J, et al. Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. J Viral Hepat 2003;10:437-45.
12. Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C Thromb Haemost 2000;83:807-10.
13. Shields PL, Mutimer DJ, Muir D, et al. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 2000;108:254-8.
14. Santagostino E, De Filippi F, Rumi MG, Rivi M, Colombo M, Mannucci PM; Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 2004;44:790-4.
15. Schulman S, Kinnman N, Lindmarker P, von Sydow M. A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Haemophilia 2002;8:129-35.
16. Meijer K, Haagsma EB, van der Meer J; CHARIBDIS Study Group. A randomized, double-blind, placebo-controlled clinical trial of high-dose interferon-alpha induction treatment combined with ribavirin for chronic hepatitis C in hemophilia. J Thromb Haemost 2004;2:194-6.
17. Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002;36:967-72.
18. Zeuzem S, Powlotsky JM, Lukasiewicz E, et al; DITTO-HCV Study Group. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250-7.
19. Karino Y, Toyota J, Sugawara M, et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003;18:404-10.
20. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004;40:1260-5.
21. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004;189:964-70.